Adverse events in small dogs treated with a single dose of vinblastine.

Vinblastine 2.0 mg/m² in small dogs causes significant neutropenia requiring close monitoring.

This retrospective study evaluated adverse events following single-dose intravenous vinblastine (VBL) administration at 2.0 mg/m² in 40 small dogs (< 10 kg) with malignant tumors. Myelosuppression was the primary concern, with neutropenia occurring in 82.5% of dogs, including severe (Grade 3-4) events in 32.5%. Thrombocytopenia was rare at 5.0%. Gastrointestinal toxicity was generally mild, with diarrhea most common (25%), followed by inappetence and vomiting (7.5% each). Febrile neutropenia developed in 5% of cases. The findings indicate that while gastrointestinal tolerability remains acceptable at this dosage, significant myelosuppression necessitates close monitoring. Importantly, the authors suggest that dose escalation protocols established for larger dogs may not be appropriate for small-breed dogs, as higher doses may exceed safety thresholds in this population.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.